Shares of other companies:
April 24, 2024 Google’s Third Cookie Phaseout Delay Amid Regulatory Hurdles
April 19, 2024 Bitcoin Halving: Catalyst for New Price Heights?
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
Tesla Is An AI Company That The Market Won’t Reward For Now
April 24, 2024
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
INCY Stock News and Mentions of Incyte Corp. Stocktwits
Updated: April 25, 2024 (13:15)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Incyte Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Incyte Corp. (INCY).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Incyte stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Incyte Corp. (INCY)
April 25, 2024 (18:28) / "Zacks Commentary" (by Zacks Equity Research)
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
In Article Trend: Neutral
April 24, 2024 (22:51) / "Forbes" (by Katie Jennings)
InnovationRx: Chelsea Clinton Invests In 24/7 Pediatrics Startup
InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. he U.S. healthcare system is not set up to take care of a kid with a rash or a fever at 2 a.m. who may not be sick enough for the emergency room, but whose parents could use a doctor.
In Article Trend: Neutral
April 24, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Allogene Therapeutics ( ALLO ) Expected to Beat Earnings Estimates: Should You Buy?
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 23, 2024 (19:03) / "Benzinga" (by Vandana Singh)
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends - Incyte ( NASDAQ:INCY )
Tuesday, Incyte Corporation INCY agreed to acquire Escient Pharmaceuticals for $750 million. Escient's pipeline includes EP262, a small molecule antagonist of Mas-related G protein-coupled receptor X2 ( MRGPRX2 ) , and EP547, a first-in-class oral MRGPRX4 antagonist.
In Article Trend: Somewhat-Bullish
April 23, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Incyte ( INCY ) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 23, 2024 (13:44) / "Zacks Commentary" (by Zacks Equity Research)
Incyte ( INCY ) to Report Q1 Earnings: What's in the Cards?
Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
In Article Trend: Somewhat-Bullish
April 12, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
In Article Trend: Bullish
April 11, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
Novartis ( NVS ) to Undertake Job Cuts in Development Department
Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.
In Article Trend: Somewhat-Bullish
April 9, 2024 (16:02) / "Zacks Commentary" (by Zacks Equity Research)
Agilent ( A ) is Set for Analytica 2024 With Advanced Products
Agilent (A) plans to showcase its new products for analytical laboratories at Analytica 2024, boosting its overall product portfolio.
In Article Trend: Somewhat-Bullish
April 2, 2024 (04:30) / "GlobeNewswire" (by HUTCHMED (China) Limited)
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
- NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July ...
In Article Trend: Neutral
April 1, 2024 (12:30) / "GlobeNewswire" (by China Medical System Holdings Ltd.)
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
HONG KONG, China and WILMINGTON, Del., April 01, 2024 ( GLOBE NEWSWIRE ) -- China Medical System Holdings Limited ( "CMS" or the "Group" ) and Incyte ( Nasdaq:INCY ) ( "Incyte" ) are pleased to announce that on 31 March 2024, that the Group, through a wholly-owned dermatology medical aesthetic ...
In Article Trend: Neutral
March 27, 2024 (15:00) / "Zacks Commentary" (by Zacks Equity Research)
Mesoblast ( MESO ) to File Pediatric GVHD Drug BLA, Stock Up
Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.
In Article Trend: Neutral
March 14, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Incyte ( INCY ) Up 1.8% Since Last Earnings Report?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 12, 2024 (17:52) / "Zacks Commentary" (by Zacks Equity Research)
Incyte ( INCY ) Posts Positive Results on Opzelura From HS Study
Incyte's (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.
In Article Trend: Neutral
March 8, 2024 (05:30) / "Motley Fool" (by Motley Fool Transcribing)
MacroGenics ( MGNX ) Q4 2023 Earnings Call Transcript
MGNX earnings call for the period ending December 31, 2023.
In Article Trend: Somewhat-Bullish
February 29, 2024 (18:08) / "PR Newswire" (by Elanco Animal Health)
Elanco Animal Health is Executing on Plan to Deliver for Shareholders
Ancora Nominates Director Candidates Despite Elanco's Meaningful Operational Progress and Good Faith Engagement with the Investor
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website